Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest
The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck.
The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs.
First run in November 2013, the MI-IAP allows researchers to easily ...
Joel Liederman, MaRS Innovation's vice-president of Business Development and Commercialization for physical sciences, is attending BioTransfer 2014 on March 18 to chair the Medical Devices Committee.
This is the first year that Toronto is hosting the BioTransfer conference. Presenters at the one-day event will discuss biotherapeutics, diagnosis and medical technology. The conference's goal is to share knowledge on current trends in the industry and to stimulate collaboration with private sector companies.
As chair, Liederman will open the medical devices committee panel discussion on Tuesday afternoon ...
MaRS Innovation's President and CEO, Dr. Raphael (Rafi) Hofstein, was appointed to the Quebec Consortium for Drug Discovery (CQDM) Board of Directors on February 18.
CQDM is a Quebec-based not-for profit that funds and supports joint projects in private and biopharmaceutical sectors.
Here's an excerpt from CQDM's announcement:
Dr. Hofstein, actively involved in the field of biotechnology, partnerships and technology transfer for over 30 years, greatly contributed to defining Israel as a world leader in biotechnology. In Israel, Dr. Hofstein held various positions including R & D Manager ...
OtoSim™ device’s integration into medical students’ curriculum to help improve diagnosis accuracy by 44 per cent
TORONTO, ON (Feb. 5, 2014) — The University of Toronto (U of T) is creating a Student Training Fund in Otoscopy in partnership with OtoSim Inc., thanks to a $200,000 donation led by Mr. Ralph Chiodo, founder of Active Green + Ross. Other donors include some franchisees of Active Green + Ross and others among Chiodo’s friends and associates.
The Halldale Group, a publisher specializing in simulation ...
Deal led by MaRS Innovation and Innovation York to strengthen Slyce’s mobile image recognition application for retail e-commerce
TORONTO, Feb. 4, 2014—Slyce today announced that it has acquired a computer vision technology developed at York University that quickly analyzes and aggregates similar images.
Through the acquisition, Slyce also hired former York PhD student, Dr. Ehsan Fazl-Ersi, to lead the integration of the intellectual property into Slyce’s Visual Search Platform as their new head of Research & Development.
Slyce is a premium provider of visual ...
Crowdmark, a MaRS Innovation and University of Toronto start-up incubated through the UTEST program, has reached a deal with Ricoh Canada Inc.
Announced January 20, 2014, the deal outlines national printing and scanning service for Crowdmark customers, with U.S. discussions coming up in the future, to improve the start-up's online marking process for teachers.
Here's an excerpt from the release (emphasis ours):
Toronto, Ontario (January 20, 2014) – Crowdmark Inc., a software company that delivers an ultra-scalable collaborative assessment platform to educators worldwide, announced today ...
MI portfolio company actively seeking additional products for licensing and development
TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.
Triphase Accelerator's announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing.
Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the ...
2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio.
1. MaRS Innovation secures a $15 million CECR funding extension
In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada.
This achievement reflects and recognizes the quality of the startups and licensable technologies within the MaRS Innovation portfolio, as well as the rigour of its business model and the achievements of its ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.
Read the original release via The National Post or in French. MaRS Innovation's November 25 announcement about the partnership is also available.
This story was covered by GEN: Genetic Engineering Biotechnology News.
Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in ...